

Drug Utilization Review Board

(DUR Board)

Meeting – May 12, 2010 @ 6:00 p.m.

Oklahoma Health Care Authority

4545 N. Lincoln Suite 124

Oklahoma City, Oklahoma 73105

Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. February 10, 2010 DUR Minutes – Vote
 - B. February 11, 2010 DUR Recommendation Memorandum
 - C. Correspondence

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for November 2009
 - B. Retrospective Drug Utilization Review for December 2009
 - C. Retrospective Drug Utilization Review Response for September 2009
 - D. Retrospective Drug Utilization Review Response for October 2009
 - E. Medication Coverage Activity Audit for March & April 2010
 - F. Help Desk Activity Audit for March & April 2010

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

5. **Action Item – Vote to Prior Authorize Mozobil[®], Nplate[®], and Arcalyst[®] – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

6. **30 Day Notice to Prior Authorize Ilaris[®] – See Appendix D.**
- A. Product Summary
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

7. **30 Day Notice to Prior Authorize Besivance[™] – See Appendix E.**
- A. Product Summary
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Chonlahan, Dr. Muchmore, Chairman

8. **30 Day Notice to Prior Authorize Requip XL[™] and Mirapex ER[™] – See Appendix F.**
- A. Requip XL[™] Product Summary
 - B. Mirapex ER[™] Product Summary
 - C. Cost Comparison
 - D. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. **30 Day Notice to Prior Authorize Lovaza[®] – See Appendix G.**
- A. Product Summary
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

10. **Action Item – Annual Review of Statins & Statin Combination Products and 30 Day Notice to Prior Authorize Livalo[®] – See Appendix H.**
- A. Current Prior Authorization Criteria
 - B. Utilization Review
 - C. Market News and Update
 - D. COP Recommendations
 - E. Utilization Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

11. **Action Item – Annual Review of Antidepressants and 30 Day Notice to Prior Authorize Oleptro[™] – See Appendix I.**
- A. Current Prior Authorization Criteria
 - B. Utilization Review
 - C. Market News and Update
 - D. COP Recommendations
 - E. Oleptro[™] Product Details

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

- 12. FDA and DEA Updates – See Appendix J.**

- 13. Future Business**
 - A. Annual Review of Smoking Cessation Products
 - B. Annual Review of Growth Hormones
 - C. Utilization Review of Epilepsy Medications
 - D. New Product Reviews

- 14. Adjournment**